Pfizer
Search results
News about Eli Lilly, Novo Nordisk, stock
News about Eli Lilly, Q2 2024, quarterly dividend
Also in the news
We’re a medicine company turning science into healing to make life better for people around the world. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges.
Lilly at a Glance. A heritage 148 years strong: company founded on May 10, 1876. Headquarters located in Indianapolis, Indiana, U.S.A. More than 44,000 employees worldwide. Approximately 10,000 employees engaged in research and development. Clinical research conducted in more than 55 countries.
Six Generations of Caring and Discovery. The Lilly story began more than 140 years ago, when founder Colonel Eli Lilly combined scientific rigor and passion for discovery, with caring for the individuals and communities the company served. Employees honor his legacy by embodying his call to "Take what you find here and make it better and better."
Current Medicines. For more than 140 years, we have worked tirelessly to develop and deliver trusted medicines and diagnostics that meet real needs. Our growing portfolio of medicines includes treatments in the areas of bone muscle joint, cancer, cardiovascular, diabetes, endocrine, immunology, neurodegeneration, neuroscience, and pain.
Nov 8, 2023 · INDIANAPOLIS, Nov. 8, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.
Feb 6, 2024 · INDIANAPOLIS, Feb. 6, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the fourth quarter of 2023. "2023 was a year of tremendous achievement for Lilly , which delivered life-changing medicines to more patients than ever before resulting in strong revenue growth," said David A. Ricks , Lilly 's ...
Oct 26, 2023 · INDIANAPOLIS, Oct. 26, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh™ (mirikizumab-mrkz) infusion (300 mg/15 mL)/injection (100 mg/mL), the first and only interleukin-23p19 (IL-23p19) antagonist for the treatment of moderately to severely active ...
